The key issue we also need to consider is that TIGIT binds to CD112 and CD113 ligands, in addition to CD155 ligands, on the surface of myeloma cells, but our experiments did not observe significant changes in the expression of the remaining ligands after EZH2 inhibitor treatment [26]. The gene discussed is NECTIN2; the disease is plasma cell myeloma.